Deebya Sarita, Bipin Bihari Panda


The present study is planned to evaluate the safety of gliclazide (antidiabetic) therapy in the presence of rosuvastatin (antihyperlipidemic) in normal and diabetic rats. Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide, rosuvastatin, and their combination. Blood samples were collected from rats at different time intervals and were analyzed for blood glucose levels. Gliclazide produced significant (p<0.05) hypoglycaemic and antihyperglycemic activity in normal and diabetic rats with peak activity 8 hours. Rosuvastatin alone produced minor reduction in blood glucose levels in normal rats. It also produced significant (p<0.05) reduction in blood glucose levels diabetic rats in repeated doses. Rosuvastatin on repeated use also significantly increased (p<0.05) the hypoglycaemic effect of gliclazide in diabetic rats when administered together. The interaction observed may be due to pharmacokinetic interaction at metabolic and excretion levels.


Combination therapy, Rosuvastatin, Gliclazide, alloxan, blood sugar

Full Text:

Full text in pdf


Adult Treatment Panel III, (2001): Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults JAMA, 285: p.2486–2497.

American Diabetes Association, Diagnosis and classification of diabetes mellitus (2006): Diabetes Care, 29 (Suppl. 1) S43-S48.

Bonora, E., Kiechl, S., Willeit, J., Oberhollenzer, F., Egger, G., (2004): Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals the Bruneck Study. Diabetes, 53(7), p.1782-89.

Das, A.K., Joshi, S.R., Yajnik, C.S., Shah, S., Prasanna, K.M., (2010): Current Status of Diabetes in India and Need for Novel Therapeutic Agents. J Assoc Physicians India, 58, p.7-9.

Davidson M. H, (2004): Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert opin drug Saf., 3(6), p.547-57.

Elliot, D. J., Lewis, B. C., Gillam, Elizabeth, M. J., Birkett, D. J., Gross, A. S., Miners, John O.; M. J. O., (2007): Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination, Brit. J. Clin. Pharmacol., 64 (4), p.450–7.

Ferner,R. E., Chaplin, S. (1987): The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs, Clini Pharmacokine, 12, p.379–401.

Gribble, F.M., Tucker, ,S. J., Seino, S., Ashcroft, ,F. M. (1998): Tissue specificity of sulfonylureas studies on cloned cardiac and β- cell KATP channels, Diabetes, 47, p.1412–1418.

Harrower, A. D., (1991): Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM, Diabetes Res. Clini Pract., 14, supplement 2, S65– S67.

Kharat, A., Ramteke, K., Kharat, K., (2015): Evaluation of anti-inflammatory and analgesic potential of methanolic extract of ceiba pentandra, Biopharm J. 1(1), 22-26.

McCormick A.D., McKillop D., Butters C.J., et al. (2000): ZD4522 — an HMG-CoA reductase inhibitor frees of metabolically mediated drug interactions: Metabolic studies in human in vitro systems. J Clin Pharmacol 40, p.1055.

Okokon, J.E., Antia, B. S., (2005): Hypoglycemic activity of aqueous leaf extract of Persea americana Mill, Ind. J. Pharmacol., 37(5), p.325-326.

Pan, H. Y., DeVault, A. R., Swites,B. J. et al., (1990): Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia, Clin. Pharmacol Therap., 48, p.201–207.

Sundaram A, Moses C.R.A. (1998): Newer antidiabetic drugs, Int. J. Diab. Dev. Countries, 18, p.24-30.

Ziegler, O., Drouin, P. (1994); Haemobiological properties of gliclazide, J. Diabetes Complications, 8, p.235–239.


  • There are currently no refbacks.

Copyright © 2015 BIOPHARM JOURNAL  - ISSN 2454-1397 & Powered by Sona Nfinity